NSE:GRANULES

Granules India Gets Sole First-to-File Status for Sodium Oxybate Extended-Release for Oral Suspension

Granules India (NSE:GRANULES, BOM:532482) has received sole first-to-file (FTF) status for its abbreviated new drug application (ANDA) for Sodium Oxybate Extended-Release for oral suspension, according to a Monday filing to the Indian stock exchanges.The drug is a generic equivalent of Alkermes' LUMRYZ, an extended-release oral suspension, which is used to treat cataplexy or excessive daytime sleepiness in patients with narcolepsy.This is Granules' second sole FTF ANDA after Amphetamine Extended-Release Tablets, the generic equivalent of Dyanavel.The company's shares were up over 2% in recent trade.

Sushil Finance Starts Granules India at Buy with INR963 Price Target

Granules India (NSE:GRANULES, BOM:532482) has an average rating of buy and mean price target of 852.12 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Choice Equity Broking Downgrades Granules India to Add from Buy; Price Target is INR835